Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia
- 1 February 2011
- journal article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 136-138
- https://doi.org/10.3816/clml.2011.n.031
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclastsLeukemia, 2007
- Role of B-Cell–Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow MicroenvironmentCancer Research, 2006
- BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myelomaLeukemia, 2006
- B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemiaBlood, 2006
- The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureBlood, 2005
- BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneBlood, 2004
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004
- BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFFScience, 2001
- BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell GrowthThe Journal of Experimental Medicine, 1999
- NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor SuperfamilyScience, 1997